کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
1855602 1529400 2016 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Muscle-invasive bladder cancer treated with TURB followed by concomitant boost with small reduction of radiotherapy field with or without of chemotherapy
ترجمه فارسی عنوان
سرطان مثانه عضلانی تهاجمی تحت درمان با TURB به دنبال افزایش همزمان با کاهش کمی زمینه پرتودرمانی با یا بدون شیمی درمانی
کلمات کلیدی
عضله تهاجمی سرطان مثانه؛ درمان محافظه کارانه رادیکال؛ پرتودرمانی؛ افزایش همزمان
موضوعات مرتبط
مهندسی و علوم پایه فیزیک و نجوم فیزیک هسته ای و انرژی بالا
چکیده انگلیسی

AimTo evaluate the clinical outcome and toxicity of the treatment of muscle-invasive bladder cancer (MIBC) that combined transurethral resection of bladder tumor (TURB) with “concomitant boost” radiotherapy delivered over a shortened overall treatment time of 5 weeks, with or without concurrent chemotherapy.BackgroundLocal control of MIBC by bladder-sparing approach is unsatisfactory. In order to improve the effectiveness of radiotherapy, we have designed a protocol that combines TURB with a non-conventionally fractionated radiotherapy “concomitant boost”.Materials and methodsBetween 2004 and 2010, 73 patients with MIBC cT2-4aN0M0, were treated with “concomitant boost” radiotherapy. The whole bladder with a 2–3 cm margin was irradiated with fractions of 1.8 Gy to a dose of 45 Gy, with a “concomitant boost” to the bladder with 1–1.5 cm margin, during the last two weeks of treatment, as a second fraction of 1.5 Gy, to a total dose of 60 Gy. Radiochemotherapy using mostly cisplatin was delivered in 42/73(58%) patients, 31/73(42%) patients received radiotherapy alone.ResultsAcute genitourinary toxicity of G3 was scored in 3/73(4%) patients. Late gastrointestinal toxicity higher than G2 and genitourinary higher than G3 were not reported. Complete remission was achieved in 48/73(66%), partial remission in 17/73(23%), and stabilization disease in 8/73(11%) patients. Three- and five-year overall, disease specific and invasive locoregional disease-free survival rates were 65% and 52%, 70% and 59%, 52% and 43%, respectively.ConclusionsAn organ-sparing approach using TURB followed by radio(chemo)therapy with “concomitant boost” in patients with MIBC allows to obtain long-term survival with acceptable toxicity.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Reports of Practical Oncology & Radiotherapy - Volume 21, Issue 1, January–February 2016, Pages 31–36
نویسندگان
, , , ,